Released Nov 7, 2012, after the close
10-Q filed Nov 7, 2012, 38 days after period end · 0001144204-12-060041
Q3 2012 · 10-Q
Revenue$3.72M$3.72M +229.0% vs Q3 2011−85.7% vs Q2 2012
Net Income-$5.48M-$5.48M N/M vs Q3 2011N/M vs Q2 2012
EPS Diluted$0.06$0.06 N/M vs Q3 2011−40.0% vs Q2 2012
Gross Profit$3,023,000+346.5%
Operating Income-$5,560,000N/M
Operating Cash Flowderived-$8,029,000N/M
Free Cash Flowderived-$8,799,000N/M
Margins · derived
Gross margin81.2%+21.4 pt vs Q3 2011
Operating margin-149.3%+625.2 pt vs Q3 2011
Net margin-147.1%+636.9 pt vs Q3 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|
| Revenue | $3.72M | $1.13M | $3.18M |
| Net Income | -$5.48M | -$8.88M | -$2.47M |
| EPS Diluted | $0.06 | -$0.10 | $0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR